medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2010, Número 3

<< Anterior Siguiente >>

Rev Biomed 2010; 21 (3)


Estado actual de las vacunas contra el Dengue. Perspectivas

Zambrano-Mora BM

Idioma: Español
Referencias bibliográficas: 40
Paginas: 197-211
Archivo PDF: 348.04 Kb.


RESUMEN

El dengue continúa extendiéndose más allá de las regiones tropicales y subtropicales y se ha convertido en un problema creciente de Salud Pública en las áreas endémicas, con un aumento importante en la incidencia y en la mortalidad. Las medidas de control no han logrado ser suficientes, y no se dispone de medidas específicas de tratamiento y prevención. En las últimas décadas se han hecho avances en el diseño de vacunas contra el dengue, con tecnologías innovadoras. La mayoría de estas vacunas se encuentra en etapas pre-clínicas del desarrollo y sólo algunas han alcanzado las fases clínicas, con resultados prometedores. Se espera poder contar en un futuro cercano con una vacuna contra el dengue, que complemente las estrategias existentes de control de esta enfermedad. Esta es una revisión del estado actual de las vacunas en desarrollo. Además, se incluye información sobre los lineamientos que la OMS ha coordinado para la realización de ensayos clínicos y aspectos regulatorios a considerar para el registro futuro de estas vacunas contra el dengue.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Guzmán MG, García G, Kourí G. Temas de Actualidad: El Dengue y Dengue Hemorrágico: Prioridades de Investigación. Rev Panam Salud Pública 2006; 19(3):204-15.

  2. San Martín JL, Brathwaite O, Zambrano B, Solórzano JO, Bouckenooghe A, Dayan G, et al The epidemiology of Dengue in the Americas over the last three decades: A worrisome reality. Am J Trop Med Hyg 2010; 82(1):128-35.

  3. Organización Panamericana de la Salud. Number of reported cases of dengue and dengue hemorrhagic fever (DHF), Region of the Americas (by country and subregion). Washington, DC, Pan American Health Organization, [1 screen]. Disponible en URL: http://www.paho.org/english/ad/dpc/cd/dengue.htm

  4. Organización Panamericana de la Salud. Alertas Epidemiológicas. Alerta epidemiológica. Brote de dengue en las Américas, 7 Julio 2010 [7 screens]. Disponible en URL: http://new.paho.org/hq/index.php?lang=es

  5. Whahab HA, Yusof R, Raham NA. A Search for Vac-Vaccines and Therapeutic for Dengue: A Review. Current Computer-Aided Drug Design 2007; 3:101-12.

  6. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenchjes E, et al. Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion. Cell 2002; 108:717 – 25.

  7. Deubel V. Approche vaccinale de la dengue. Médecine et Maladies infectieuses 1995; 25(7):696-701.

  8. Anónimo. Dengue Vaccine. JAMA 1945; 128(14):1026-7.

  9. Simmons JS. Dengue Fever. Am J Trop Med Hyg 1931; XI(2):77-101.

  10. Vaughn DW, Withehead SS, Durbin AP. Viral Vacccines. Dengue. En: Barret ADT and Stanberry LW, editores. Vaccines for Biodefense and Emerging and Neglected Diseases. Oxford: Elsevier; 2009. Vol III, Chapt 19, pp. 289-324.

  11. Sabin AB, Schlesinger W. Production of immunity to dengue with virus modified by propagation in mice. Science 1945; 101(2364):640-2.

  12. Wisseman Jr ChL, Sweet BH, Rosenzweig EC, Eylar OR. Attenuated living Type 1 Dengue. Vaccine. Am J Trop Med Hyg 1963; 12:620-2.

  13. Bellanti JA, Bourke ATC, Buescher EL, Cadigan FC, Cole GA, Batawi YE et al. Report of Dengue vaccine field trial in the Caribbean, 1963: A collaborative study. Bull World Health Organ 1966; 35(1):93.

  14. Henchal EA, Putnak R. The Dengue viruses. Clin Microbiol Rev 1990; 3(4):376-96.

  15. Bhamarapravati N, Yoksan Sutee. Live attenuated tetravalent dengue vaccine. En: Gubler DJ and Kuno G, editores. Dengue and Dengue Hemorrhagic Fever.Wallingford: CABI Publishing; 1997. pp. 367-77.

  16. Halstead SB, Vaughn DW. Dengue Vaccines. En: Plotkin S, Ornestein W, Offit P, editores. Vaccines. 5ta ed. Philadelphia: WB Saunders; 2008. pp.1155-61.

  17. Chanthavanich P, Luxemburger C, Sirivichayakul C, Lapphra K, Pengsaa K, Yoksan S et al short report: Immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg 2006; 75(1):26-8.

  18. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. [Review]. [fe de erratas publicada en Lancet Infect Dis 2010; 10:304]. Lancet Infect Dis 2009; 9:678-87.

  19. Guy B, Guirakhoo F, Barban V, Higgs S, Monath T and Lang J. Preclinical and clinical development of YFV-17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. (Review). Vaccine 2010; 28:632-49

  20. Guilarde AO, Turchi MD, Siqueira Jr JB, Feres VC, Rocha B, Levi JE et al. Dengue and Dengue hemor-hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes and antibody response. J Infect Dis 2008; 197(6):817-24

  21. Bray M, Lay C-J. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci 1991; 88:10342-6

  22. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Raterree M et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000; 74(12):5477-85.

  23. Lang J. Recent progress on sanofi pasteur’s dengue vaccine candidate. Journal of Clinical Virology 2009; 46(Suppl 2):S20-S24.

  24. Huang-H CY, Butrapet S, Pierro DJ, Chang JG-J, Hunt AR, Bhamarapravati N et al. Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1Virus Vaccine. J Virol 2000; 74(7):3020-28.

  25. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nature Reviews Microbiology 2007; 5:518-28.

  26. Edelman R. Dengue vaccines approach the finish line. CID 2007; 45(Suppl1):S56-60.

  27. Simmons M, Burgess Y, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010; 396:280-8.

  28. Suzuki R, Winkelman ER, Mason Peter W. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J Virol 2009; 83(4):1870-80.

  29. Putnak R, Coller BA, Voss G, Vaughn DW, Clements D, Peters I et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23:4442-52.

  30. Guzmán MG, Rodríguez R, Rosmari R, Hermida H, Alvarez M, Lazo L et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with Recombinant Dengue 4 virus Envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 2003; 69(2):129-34.

  31. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, López C et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Research 2008; 80:194-9.

  32. Valdés I, Bernardo L, Gil L, Pavon A, Lazo L, Lòpez C et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009; 394:249-58.

  33. Lengh CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes and Infection. 2009; 11(2):288-95.

  34. Kochel T, Wu SJ, Raviprakash K, Hobart P, Hoffman S, Porter K and Hayes C. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine. 1997;1 5:547-52.

  35. Blair PJ, Kochel TJ, Raviprakash K, Guevara C, Salazar M, Wu SJ et al. Evaluation of immunity and protective efficacy of a dengue-3 premembrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine 2006; 24:1427-32.

  36. Ramanathand MP, Kuo YC, Selling BH, Li Q, Sardesai NY, Kim JJ, et al. Development of a novel DNA SynCon™ tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine 2009; 27:6444–53.

  37. World Health Organization. Immunization, Vaccines & Immunobiologicals. Guidelines for the clinical evaluation of dengue vaccines in endemic areas, 2008. WHO/IVB/08.12. Disponible en URL: http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.12_eng.pdf

  38. World Health Organization. Immunization, Vaccines & Immunobiologicals. Guidelines for plaque reduction neutralization test for human antibodies to dengue viruses, 2007. WHO/IVB/07.07. Disponible en URL: http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.07_eng.pdf

  39. World Health Organization. Guidelines for the production and quality control of candidate tetravalent dengue virus vaccines (live). WHO Technical Report Series Nº 932, 2006 Annex 1, pp-44-72 Disponible en URL: http://www.who.int/biologicals/publications/trs/areas/vaccines/dengue/TRS932Annex%201_Dengue%20virus%20vacc%20live.pdf

  40. World Health Organization. Meeting Report. WHO working group on Technical specifications for manufacture and evaluation of dengue vaccines, May 2009. pp 1-38. Disponible en URL: http://www.who.int/biologicals/publications/meetings/areas/vaccines/dengue/DENGUE_2009_Final_WHO_REP_2010.pdf




2020     |     www.medigraphic.com